این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Medical Sciences، جلد ۴۸، شماره ۱، صفحات ۹۱-۹۷
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی The Role of Immunosuppression in the Development of COVID-19 in Systemic Lupus Erythematosus Patients: A Brief Report
چکیده انگلیسی مقاله Recently, due to the coronavirus disease 2019 (COVID-19) pandemic, much concern has been raised about patients with chronic diseases who may become more susceptible to the disease. The present cross-sectional study aimed to characterize the clinical course of COVID-19 in patients with systemic lupus erythematosus (SLE). In addition, a possible correlation between the immunosuppression state and the incidence of COVID-19 is investigated. In May 2020, 500 SLE patients registered in the database of Golestan Rheumatology Research Center (Golestan province, Iran) were selected for this cross-sectional study. Using a questionnaire, patients were contacted by telephone to collect data including demographic characteristics, disease status, drug use, and new clinical symptoms. Data were analyzed using SPSS software version 24.0. Of the 500 selected patients, 355 responded to the phone calls and subsequently enrolled in the study. Among the enrolled patients, 25 were classified as COVID-19 positive, including eight hospitalized patients, of which two required intensive care and subsequently died. COVID-19 incidence was significantly lower in the immunosuppressed patients (2.2% vs. 10%, P=0.01). There was no significant correlation between hydroxychloroquine consumption and the incidence of COVID-19 in SLE patients. Fever, fatigue, dyspnea, and dry cough were the most common clinical symptoms. Our results showed that COVID-19 incidence was lower in immunosuppressed than the non-immunosuppressed SLE patients. Further studies are required to substantiate the role of immunosuppression in the development of COVID-19.A preprint version of this study was published at https://www.researchsquare.com/article/rs-78704/v1 with doi: https://doi.org/10.21203/rs.3.rs-78704/v1
کلیدواژه‌های انگلیسی مقاله COVID-19, systemic lupus Erythematosus, Hydroxychloroquine, Immunosuppression, SARS-CoV2
نویسندگان مقاله Mohammadrafi Damirchi |
Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Mehrdad Aghaie |
Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Sima Sedighi |
Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Samaneh Tavassoli |
Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Gholamreza Roshandel |
Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran

Mohammadjavad Hassani |
Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Nafiseh Abdolahi |
Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran

نشانی اینترنتی https://ijms.sums.ac.ir/article_48769_14674a651514c60eb3c8609befb965cd.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات